A Phase 1 interventional study of OCU200 in Center Involved Diabetic Macular Edema and Diabetic Macular Edema, sponsored by Ocugen. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Ocugen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 276 studies in Macular Edema with a site in United States — 16 open to participants now, 32 under way, 11 of them phase 3. Macular Edema · United States.
Among the 276 studies in Macular Edema with a site in United States, this one is the 159th largest by planned enrollment of the 244 interventional ones that give a count, is one of 9 that started in 2024, is one of 43 in phase 1, reaches primary completion later than 5 of the 31 other live ones, and was the 244th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →16 of the 276 studies in Macular Edema with a site in United States are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Israel and 1 more country
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 1 more country
Ages 18+
Kodiak Sciences Inc · Sites in United States, Argentina
Ages 18+
Massachusetts Eye and Ear Infirmary · Sites in United States
Ages 18+
Boehringer Ingelheim · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
276 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 74 · Phase 2 101 · Phase 3 57 · Phase 4 33
First in 1992; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 56 across 587 interventional studies indexed under Macular Edema.
Median enrollment 45 across the 244 interventional studies, 60 across the 30 observational. Of the 223 that completed or were terminated, 131 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
133 of 276 have an industry lead sponsor. The 10 most frequent:
Ocugen is the lead sponsor of 12 studies on the registry; 2 are open to participants now.
Ocugen has 1 study filed under Macular Edema — fewer than ten, so there is no comparison to draw.
11 of the studies in Macular Edema with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06957080Phase 3EyeBiotech Ltd.A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME | 2027-01-11 |
| NCT06996080Phase 3Kodiak Sciences IncA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE | 2027-02 |
| NCT06990399Phase 3Kodiak Sciences IncA Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK | 2027-04 |
| NCT04108156Phase 3Hoffmann-La RocheA Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME | 2027-07-20 |
| NCT07449923Phase 3EyePoint Pharmaceuticals, Inc.CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME | 2027-10 |
Add all 11 to your calendar (.ics) → With an account.
Among the 276 studies in Macular Edema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase 1 study to assess the safety and efficacy of OCU200 for center-involved diabetic macular edema
This is a multicenter, open-label, dose ranging study with 4 cohorts in the dose-escalation portion of the study. An accelerated 3+3 design with parallel and sequential dosing will be used.
Under the escalation design, 12 subjects will be enrolled if there are no DLTs and up to 24 subjects under the condition that exactly 1 of the 3 subjects of every cohort if determined to have a DLT.
Each subject will receive a total of 2 intravitreal injections of OCU200 6 weeks apart.
The DSMB will review the sentinel subject 1 week safety data post dosing in every cohort of all 3 subjects.
Cohort 1: 3+3 participants will receive intravitreal injection of OCU200.
Cohort 2: 3+3 participants will receive intravitreal injection of OCU200.
Cohort 3: 3+3 participants will receive intravitreal injection of OCU200.
Cohort 4: 3+3 participants will receive intravitreal injection of OCU200.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Central-involved DME with central retinal subfield thickness (CST) values, as assessed with spectral-domain optical coherence tomography (SD-OCT) of:
Note: The last anti-VEGF injection must be administered at least six weeks (45 days) prior to the study treatment (Day 1) in the study eye.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3+3 participants will receive intravitreal injection of OCU200 (0.5 mg/mL concentration).
Drug: OCU200
3+3 participants will receive intravitreal injection of OCU200 (1 mg/ML concentration).
Drug: OCU200
3+3 participants will receive intravitreal injection of OCU200 (2 mg/mL concentration).
Drug: OCU200
3+3 participants will receive intravitreal injection of OCU200 (5 mg/mL concentration).
Drug: OCU200
Intravitreal Injection
Study Drug-related adverse events (SDAE)
Counts, frequencies and percentages of SDAEs.
Time frame: 24 weeks
Treatment-emergent adverse events (TEAEs)
Counts, frequencies and percentages TEAEs.
Time frame: 24 weeks
Serious adverse events (SAEs)
Counts, frequencies and percentages of SAEs.
Time frame: 24 weeks
Best-corrected visual acuity (BCVA)
Measured as the ETDRS letter score on the EVA tester or E-ETDRS charts.
Time frame: 24 Weeks (Changes from baseline)
Intraocular pressure (IOP)
IOP measurement by applanation or rebound tonometry.
Time frame: 24 weeks(Changes from baseline)
Color fundus photography
Color fundus photographs will be taken to evaluate retinal anatomy and grade diabetic retinopathy severity scale (DRSS).
Time frame: 24 Weeks(Changes from baseline)
Spectral Domain Optical Coherence Tomography (SD-OCT)
SD-OCT will be utilized to assess retinal thickness. OCT images and scans will be transmitted to a central reading center for independent analysis.
Time frame: 24 Weeks(Changes from baseline)
Spectral Domain Optical Coherence Tomography Angiography (SD-OCTA)
SD-OCTA will be utilized to assess retinal vasculature and images will be transmitted to a central reader for independent analysis.
Time frame: 24 weeks (Changes from baseline)
Wide-field Fluorescein Angiography (wf-FA)
wf-FA will be conducted at screening and EOS visits to assess central and peripheral vasculature.
Time frame: 24 weeks (Changes from baseline)
Improvement of diabetic retinopathy severity scale (DRSS)
Proportion of participants with ≥ 2-step improvement of diabetic retinopathy severity scale (DRSS)
Time frame: 24 weeks
Change from baseline in BCVA letters.
Dose response as assessed by mean change from baseline in BCVA letters and mean number of injections by study visit
Time frame: 24 weeks
Reduction of CST
The proportion of participants having a ≥ 10% reduction of CST at Week 13 and Week 19
Time frame: 24 Weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Jul 2026, 30 months after the start.
Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 30 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ocugen